Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 2, 2010, Pages 210-213

  Kang, Keon Wook ^a   Chun, Myung Kwan ^a   Kim, Ok ^a   Subedi, Robhash Kusam ^a   Ahn, Sang Gun ^a   Yoon, Jung Hoon ^a   Choi, Hoo Kyun ^a  

^a Chosun University   (South Korea)

Author keywords

Doxorubicin; Doxorubicin resistant breast cancer; Multidrug resistance; P glycoprotein; Solid lipid nanoparticles

Indexed keywords

BREAST CANCER; DOXORUBICIN; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; SOLID LIPID NANOPARTICLES;

CELL CULTURE; CELL DEATH; DRUG THERAPY; GLYCOPROTEINS; REFRIGERATORS;

NANOPARTICLES;

DOXORUBICIN; GLYCOPROTEIN P; SOLID LIPID NANOPARTICLE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RETENTION; GENE OVEREXPRESSION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; LIPIDS; MICE; NANOPARTICLES;

EID: 77949916231     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.12.006     Document Type: Article

References (12)

1. Bolhuis H., Veen H.W., Poolman B., Driessen A.J.M., and Konings W.N. Mechanism of multidrug transporters. FEMS Microbiol Rev 21 (1997) 55-84
2. Stouch T.R., and Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Del Rev 54 (2002) 315-328
3. Consoli U., Priebe W., Ling Y.H., Mahadevia R., Griffin M., Zhao S., et al. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 88 (1996) 633-644
4. Lyer A.K., Khaled G., Fang J., and Maeda H. Exploiting the enhanced permeability and retention effect form tumor targeting. Drug Discov Today 11 (2006) 812-818
5. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 65 (2000) 271-284
6. Müller R.H., Madar K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50 (2000) 161-177
7. Kim B.D., Na K., and Choi H.K. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci 24 (2005) 199-205
8. Chawla J.S., and Amiji M.M. Biodegradable poly(x-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 249 (2002) 127-138
9. Subedi R.K., Kang K.W., and Choi H.K. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 37 (2009) 508-513
10. Han C.Y., Cho K.B., Choi H.S., Han H.K., and Kang K.W. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29 (2008) 1837-1844
11. Simon S.M. Role of organelle pH in tumor cell biology and drug resistance. Drug Discov Today 4 (1999) 32-38
12. Scovassi A.I., and Poirier G.G. Poly(ADP-ribosylation) and apoptosis. Mol Cell Biochem 199 (1999) 125-137